Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Vitamin D May Not Decrease Risk for Prostate Cancer
Link ID 6255
Title Vitamin D May Not Decrease Risk for Prostate Cancer
Url http://www.medscape.com/viewarticle/575325?src=rss
Description In a large prospective study, higher circulating serum concentrations of 25-hydroxyvitamin D were associated with an increased risk for aggressive prostate cancer. Medscape Medical News
Category Articles > Hematology-Oncology
Keywords
Date May 31, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. Monitoring of Magnetic Targeting to Tumor Vasculature Through MRI and Biodistribution
  A promising new cancer drug delivery system utilizes magnetic cationic liposomes, which can be guided to the tumor site by external magnet and monitored noninvasively with MRI. Nanomedicine
Category:   Articles > Hematology-Oncology


2. Cancer and Thrombosis: Implications of Published Guidelines for Clinical Practice
  Despite the significant burden imposed by VTE and the availability of effective anticoagulant therapies, many cancer patients do not receive appropriate, guidelines-recommended VTE prophylaxis. Annals of Oncology
Category:   Articles > Hematology-Oncology


3. What the ASCOG Z0011 Results Mean for Radiation OncologistsWhat the ASCOG Z0011 Results Mean for Rad
  The study, which changed a standard of care for surgeons, has implications for radiation therapy. Medscape Medical News
Category:   Articles > Hematology-Oncology


4. Different Ovarian Cancer Strategies for BRCA1 and BRCA2?Different Ovarian Cancer Strategies for BRCA
  Platinum-based chemotherapy might be more effective in ovarian cancers with BRCA2 mutations than in those with BRCA1 mutations. Medscape Medical News
Category:   Articles > Hematology-Oncology


5. Gefitinib Yields Superior Outcomes vs Chemotherapy in EGFR-Mutation-Positive NSCLC
  Dr. Maurie Markman comments on a study in Lancet Oncology indicating that patients with NSCLC patients who have an EGFR mutation benefit more from gefitinib than from cisplatin/docetaxel. Medscape Genomic Medicine
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS